Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now?

[1]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[2]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[3]  E. Bernal,et al.  Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study , 2002, Circulation.

[4]  S. Nattel,et al.  Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. , 2002, Cardiovascular research.

[5]  S. Connolly,et al.  Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. , 2001, The American journal of cardiology.

[6]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[7]  F. Sachs,et al.  Tarantula peptide inhibits atrial fibrillation , 2001, Nature.

[8]  S. Hohnloser,et al.  Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial , 2000, The Lancet.

[9]  M. Brodsky,et al.  Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study , 2000, Circulation.

[10]  A. Goette,et al.  Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. , 2000, Journal of the American College of Cardiology.

[11]  R M Eglen,et al.  Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. , 1999, Circulation.

[12]  L. Køber,et al.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.

[13]  W. Klaus,et al.  Increase in gap junction conductance by an antiarrhythmic peptide. , 1997, European journal of pharmacology.

[14]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[15]  Lippincott Williams Wilkins,et al.  The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1991, Circulation.

[16]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.